Intellia Therapeutics reported fourth-quarter 2025 financial results and provided updates on its CRISPR gene-editing programmes. The company ended 2025 with approximately $605 million in cash, expected to fund operations into the second half of 2027. For lonvoguran ziclumeran (lonvo-z) treating hereditary angioedema, Intellia expects Phase 3 HAELO clinical data by mid-2026, with a biologics licence application submission in the second half of 2026 and anticipated US launch in the first half of 2027. The company completed dosing of 80 patients in September 2025. For nexiguran ziclumeran (nex-z) treating ATTR amyloidosis, Intellia is reactivating global sites for the MAGNITUDE-2 Phase 3 trial following the FDA's January 2026 clinical hold lift, with enrollment completion expected in the second half of 2026. Engagement continues regarding the clinical hold on the MAGNITUDE trial.

Intellia Therapeutics shares have surged 35.4% over the past month and 35.7% year-to-date, trading around $12.50. However, the stock scores just 2 out of 6 on valuation checks, suggesting the market prices it favourably on only a couple of basic tests. A discounted cash flow analysis estimates the company's intrinsic value at $233.98 per share, implying the stock is 94.7% undervalued at current levels. The model projects Intellia moving from negative free cash flow of $420 million in the latest twelve months to positive cash flow of approximately $370 million by 2030. Despite recent gains, the stock has posted weak longer-term returns, declining 65.2% over three years and 82.5% over five years.

ARK Invest, led by Cathie Wood, has purchased approximately 145,153 shares of Intellia Therapeutics worth $1.33 million, significantly increasing its stake in the gene-editing company. The acquisition comes as the stock trades near multi-year lows between $9.00 and $9.60, funded partly through reducing positions in Roku and Shopify. The purchase contrasts sharply with Intellia's current challenges. The FDA imposed clinical holds on two key CRISPR programmes in Q4 following safety data showing significant liver damage in trial participants. The company reported a Q3 2025 net loss of $101.3 million, improved from $135.7 million the previous year. With no approved products generating revenue and regulatory uncertainty persisting, the stock remains highly speculative, valued at just over $1 billion market capitalisation.